Panacea Biotec Announces 42nd AGM on Sep 29, 2026; E-voting from Sep 26-28
Panacea Biotec Limited will hold its 42nd Annual General Meeting on September 29, 2026, via video conference. The Annual Report for FY2025-26 and AGM notice have been dispatched. Remote e-voting will be open from September 26 to September 28, 2026.
This is a standard regulatory filing for an upcoming AGM and does not involve any new financial outcomes, strategic decisions, or operational changes that would significantly impact the company's stock or business.
The announcement is a routine procedural update regarding the Annual General Meeting and does not contain any new financial information or significant business developments that would influence sentiment.
Panacea Biotec Limited has announced that its 42nd Annual General Meeting (AGM) will be held on Tuesday, September 29, 2026, at 11:30 AM IST. The meeting will be conducted through Video Conferencing (VC) / Other Audio-Visual Means (OAVM) in compliance with circulars from the Ministry of Corporate Affairs (MCA) and SEBI.
The Notice of the 42nd AGM, along with the Annual Report for the Financial Year ended March 31, 2026, has been sent to members whose email addresses are registered with the Company or Depository Participants via electronic mode on September 07, 2026. For shareholders whose email IDs are not registered, web links to access the Notice of AGM and the Annual Report have been provided.
The remote e-voting facility will be available from 9:00 AM IST on September 26, 2026, until 5:00 PM IST on September 28, 2026. The cut-off date for remote e-voting is September 22, 2026. The company also provided instructions for shareholders to register or update their email addresses and KYC details to ensure prompt communication.
What to do with a filing like this
Panacea Biotec Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Panacea Biotec Limited. Read the original for the full detail.